Cargando…
Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review
An excessive requirement for methionine (MET), termed MET dependence, appears to be a general metabolic defect in cancer and has been shown to be a very effective therapeutic target. MET restriction (MR) has inhibited the growth of all major cancer types by selectively arresting cancer cells in the...
Autores principales: | Kawaguchi, Kei, Han, Qinghong, Li, Shukuan, Tan, Yuying, Igarashi, Kentaro, Murakami, Takashi, Unno, Michiaki, Hoffman, Robert M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562625/ https://www.ncbi.nlm.nih.gov/pubmed/31052611 http://dx.doi.org/10.3390/cells8050410 |
Ejemplares similares
-
Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models
por: Kawaguchi, Kei, et al.
Publicado: (2017) -
Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model
por: Kawaguchi, Kei, et al.
Publicado: (2017) -
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
por: Murakami, Takashi, et al.
Publicado: (2017) -
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model
por: Igarashi, Kentaro, et al.
Publicado: (2018) -
MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)
por: Kawaguchi, Kei, et al.
Publicado: (2017)